Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• A known synthetic lethal interaction exists between MK2 and p53 in response to DNA damage.
• Targeting synthetic lethal interactions is a promising cancer therapy strategy.

Purpose of the Study:

• To introduce and validate the concept of augmented synthetic lethality (ASL).
• To investigate if targeting DNA repair protein XPA can enhance the MK2-p53 synthetic lethality for improved anti-tumor effects.

Main Methods:

• Utilized siRNA-peptide nanoplexes for co-delivery of gene targets.
• Tested the efficacy of targeting MK2 and XPA in a p53-deficient lung adenocarcinoma mouse model.
• Evaluated therapeutic responses alone and in combination with cisplatin chemotherapy.

Main Results:

• Loss of XPA significantly augmented the synthetic lethality between MK2 and p53.
• Co-targeting MK2 and XPA enhanced anti-tumor responses, both independently and with cisplatin.
• Improved long-term survival and cisplatin response in a challenging lung cancer model.

Conclusions:

• Augmented synthetic lethality (ASL) is a viable strategy to enhance existing synthetic lethal combinations.
• Co-targeting cell cycle checkpoints and DNA repair mechanisms offers a novel therapeutic approach.
• RNAi nanocarriers show potential for delivering combined gene therapies in vivo for cancer treatment.